权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Establishing and reversing the functional consequences of Titin truncation mutations

建立并逆转肌联蛋白截断突变的功能后果

基本信息

批准号：
10640157
负责人：
STUART G CAMPBELL
金额：
$ 52.91万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10640157
关键词：
3-Dimensional Adrenergic Agents Agar Gel Electrophoresis Alternative Splicing Base Pairing Behavior Biological Assay Biology Biomimetics CRISPR-mediated transcriptional activation CRISPR/Cas technology Cardiac Cardiac Myocytes Cardiomyopathies Cells Clustered Regularly Interspaced Short Palindromic Repeats Communities Computing Methodologies DNA Data Dependence Development Diagnosis Dilated Cardiomyopathy Disease Distal Dose Extracellular Matrix Fibroblasts Functional disorder Future Genes Genetic Goals Guide RNA Heart Heart failure Heterozygote Human Individual Kinetics Knowledge Learning Length Lesion Link Location Measures Mechanics Mediating Methods Modeling Molecular Mus Mutation Myocardial Contraction Myocardium Nonmuscle Myosin Type IIA Organelles Pathogenesis Pathogenicity Pathologic Pathway interactions Patients Phenotype Physicians Physiological Prognosis Protein Isoforms Proteins Publications RNA Binding Reagent Regulation Regulatory Element Research Resources Risk Sarcomeres Series Signal Transduction Site Stress Structure Sturnus vulgaris Sudden Death Technology Therapeutic Tissue Engineering Tissue Model Tissue-Specific Gene Expression Transcription Coactivator Variant Western Blotting Work adverse outcome biological adaptation to stress biomarker development biomarker identification cardiac tissue engineering cohort confocal imaging connectin disease prognosis dosage genome editing heart cell heart dimension/size heart function high risk human model improved induced pluripotent stem cell induced pluripotent stem cell derived cardiomyocytes inherited cardiomyopathy insight mechanotransduction mutation carrier prevent promoter proteostasis response scaffold sudden cardiac death therapeutic development therapeutic target transcriptomics

项目摘要

PROJECT SUMMARY/ABSTRACT Cardiomyopathies occur in ~1:200 individuals and are commonly caused by inheritance of variants in genes that encode proteins that regulate the sarcomere, the force-producing organelle of heart cells. Due to an incomplete understanding of variant pathogenicity and cardiomyopathy pathogenesis, physicians are currently limited in their ability to provide diagnoses, prognoses, and therapeutic options for cardiomyopathy patients. Variants in the TTN gene, which encodes the sarcomere protein titin, are the most frequently identified genetic lesion in dilated cardiomyopathy (DCM), which is characterized by heart chamber dilation, reduced contractile function, risk of sudden death, and progressive heart failure. The most frequent type of TTN variant identified in DCM is a truncation mutation that would be predicted to shorten TTN protein length and to reduce TTN protein quantities. Significantly, truncation variants localized to distal TTN structural domains are more pathogenic than those localized to proximal structural domains, but the mechanistic basis for this relationship is uncertain. It remains incompletely understood how TTN truncation variants cause DCM generally, which is compounded by our lack of understanding of the ‘length dependence’ of TTN variant pathogenicity. These knowledge gaps limit disease prognostication, biomarker identification, and therapeutic development for DCM patients. The central goal of our study is to define how disruptions in TTN length and dosage by TTN variants cause DCM, and exploit this knowledge to develop DCM therapeutics for TTN variant carriers. We hypothesize that healthy cardiac contractile function and structure depends on the regulation of TTN length and dosage, and that varying pathogenicity of TTN truncation can be explained by distinct structural and functional consequences associated with the specific site of truncation. In Aim 1, we will determine the functional consequences of TTN truncations across structural domains by harnessing 3-dimensional heart tissue models composed of human cardiomyocytes differentiated from induced pluripotent stem cells in which variants have been introduced by CRISPR-mediated genome editing. We will interrogate these models for tissue mechanical phenotypes (such as passive tension and Frank-Starling behavior), TTN protein length and levels (using specialized methods), proteostasis stress pathway responses (using immunoblotting), and mechanotransduction signaling and alternative splicing (using expression analysis and transcriptomics, respectively). In Aim 2, we will restore TTN protein levels using the recently developed method of CRISPR activation applied to DCM engineered heart tissue models for both evaluating the function of TTN isoforms generally and as a DCM proof-of-concept therapeutic. Through these Aims, we will gain critical new insights into the pathophysiology of DCM-associated TTN truncation variants, uncover features to explain the variable pathogenicity identified in DCM patients, and develop a therapeutic to target TTN directly. We anticipate this new knowledge will improve physicians’ capacity to diagnose, prognose, and treat patients with DCM due to TTN variants.

项目摘要/摘要心肌病发生在大约1：200人中，通常是由以下基因变异引起的编码调节肌节的蛋白质，肌节是心脏细胞的产生力量的细胞器。由于一个不完整的对变异致病机制和心肌病发病机制的了解，目前医生仅限于他们为心肌病患者提供诊断、预后和治疗选择的能力。中的变体 TTN基因编码肌节蛋白titin，是人类最常见的遗传损伤扩张型心肌病(DCM)，其特征是心腔扩张，收缩功能降低，有猝死和进行性心力衰竭的风险。在DCM中发现的最常见的TTN变异类型是一种截断突变，预计会缩短TTN蛋白长度，减少TTN蛋白数量。值得注意的是，定位于TTN远端结构域的截断变体比那些局限于近端结构域，但这种关系的机制基础尚不确定。它仍然存在不完全了解TTN截断变量是如何导致DCM的，这一点由于我们缺乏了解TTN变异体致病的“长度依赖性”。这些知识差距限制了疾病扩张型心肌病患者的预后、生物标记物识别和治疗进展。的中心目标是我们的研究是定义TTN变种对TTN长度和剂量的干扰如何导致DCM，并利用这一点对TTN变异型携带者开发扩张型心肌病疗法的知识。我们假设健康的心脏收缩功能和结构依赖于TTN的长度和剂量的调节，而这种变化 TTN截断的致病性可以用不同的结构和功能后果来解释带有截断的特定位置。在目标1中，我们将确定TTN截断的功能后果利用由人心肌细胞组成的三维心脏组织模型跨越结构域 CRISPR介导的变异体诱导多能干细胞分化基因组编辑。我们将询问这些模型的组织机械表型(如被动张力和Frank-Starling行为)、TTN蛋白长度和水平(使用特殊方法)、蛋白稳定应激途径反应(使用免疫印迹)、机械转导信号和选择性剪接(使用分别是表达分析和转录组学)。在目标2中，我们将使用新开发的CRISPR激活方法在DCM工程心脏组织模型中的应用评估TTN异构体的一般功能和作为DCM概念验证治疗的作用。通过这些目的，我们将获得对DCM相关TTN截断变体的病理生理学的关键的新见解，揭示在扩张型心肌病患者中发现的不同致病性的特征，并开发一种治疗方法直接瞄准TTN。我们预计这一新知识将提高医生的诊断、预后、以及治疗由于TTN变异而导致的扩张型心肌病患者。